HC Wainwright Reaffirms “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ)

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $20.00 price objective on the stock.

TransCode Therapeutics Stock Performance

NASDAQ RNAZ opened at $0.78 on Thursday. The firm has a 50-day moving average of $5.54 and a 200-day moving average of $237.59. TransCode Therapeutics has a 52-week low of $0.65 and a 52-week high of $66.33.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.